When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
BCRX - BioCryst: Estimate-Beating Q1 But Risks Are Considerable
BioCryst Pharmaceuticals Inc.
2024-05-07 06:15:31 ET
Summary
BioCryst reported strong earnings with top and bottom line beats.
Its success reflects positive performance by its approved ORLADEYO.
ORLADEYO's $1 billion peak sales potential coupled with BioCryst's <$1 billion market cap makes it a speculative "Buy".
This is my second BioCryst ( BCRX ) article following 04/11/2022's "BioCryst: After The Fall" (" FALL "). The downdraft referenced in the title to FALL was caused by its decision to pause enrollment in phase 2 trials for BCX9930 in treatment of diverse diseases....